Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Application Due Date(s): May 17, 2022; Nov 17, 2022; May 17, 2023; Nov 17, 2023; May 17, 2024; Nov 17, 2024

PAR-22-071 Expiration Date November 18, 2024

Agency Website



Amount Description

Application budgets are limited to $475,000 in direct costs per year and need to reflect the actual needs of the proposed project

The maximum project period is 4 years.

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Translational

External Deadline

May 17, 2024